473 related articles for article (PubMed ID: 12506467)
1. [Recent advance in adjuvant therapy for breast cancer].
Shimizu C; Watanabe T
Gan To Kagaku Ryoho; 2002 Dec; 29(13):2458-69. PubMed ID: 12506467
[TBL] [Abstract][Full Text] [Related]
2. [A randomized controlled study comparing uracil-tegafur (UFT)+tamoxifen (UFT+TAM therapy) with cyclophosphamide+adriamycin+5-fluorouracil (CAF therapy) for women with stage I , II, or IIIa breast cancer with four or more involved nodes in the adjuvant setting].
Inaji H; Sakai K; Oka T; Ozawa K; Saito Y; Senoo T; Taguchi T; Terasawa T; Nakao K; Mori T; Koyama H; Oshima A
Gan To Kagaku Ryoho; 2006 Oct; 33(10):1423-9. PubMed ID: 17033231
[TBL] [Abstract][Full Text] [Related]
3. [Benefits of adjuvant chemotherapy for breast cancer].
Motomura K; Noguchi S; Inaji H; Koyama H
Gan To Kagaku Ryoho; 1997 Aug; 24(10):1239-44. PubMed ID: 9279342
[TBL] [Abstract][Full Text] [Related]
4. [Adjuvant therapy of breast cancer].
Semiglazov VF; Abzumanov AS; Bozhok AA; Ivanov VG; Ivanova OA; Barash NIu; Topuzov EE; Seleznev IK; Migmanova NSh; Popova RT; Nurgaziev KSh
Khirurgiia (Mosk); 2001; (5):52-60. PubMed ID: 11505673
[No Abstract] [Full Text] [Related]
5. Postoperative adjuvant therapy with tamoxifen, tegafur plus uracil, or both in women with node-negative breast cancer: a pooled analysis of six randomized controlled trials.
Noguchi S; Koyama H; Uchino J; Abe R; Miura S; Sugimachi K; Akazawa K; Abe O
J Clin Oncol; 2005 Apr; 23(10):2172-84. PubMed ID: 15800310
[TBL] [Abstract][Full Text] [Related]
6. Patterns of locoregional failure in patients with operable breast cancer treated by mastectomy and adjuvant chemotherapy with or without tamoxifen and without radiotherapy: results from five National Surgical Adjuvant Breast and Bowel Project randomized clinical trials.
Taghian A; Jeong JH; Mamounas E; Anderson S; Bryant J; Deutsch M; Wolmark N
J Clin Oncol; 2004 Nov; 22(21):4247-54. PubMed ID: 15452182
[TBL] [Abstract][Full Text] [Related]
7. Systemic therapy in resectable breast cancer.
Bonadonna G; Valagussa P
Hematol Oncol Clin North Am; 1989 Dec; 3(4):727-42. PubMed ID: 2691496
[TBL] [Abstract][Full Text] [Related]
8. [Clinical analysis of resectable breast cancer: a report of 6 263 cases].
Yang MT; Rong TH; Huang ZF; Zeng CG; Long H; Fu JH; Lin P; Wang X; Wang SY; Wang X; Tang J
Ai Zheng; 2005 Mar; 24(3):327-31. PubMed ID: 15757535
[TBL] [Abstract][Full Text] [Related]
9. Adjuvant systemic therapy in primary breast cancer.
Mouridsen HT; Palshof T
Acta Chir Scand Suppl; 1984; 519():43-53. PubMed ID: 6393664
[No Abstract] [Full Text] [Related]
10. Locoregional radiation therapy in patients with high-risk breast cancer receiving adjuvant chemotherapy: 20-year results of the British Columbia randomized trial.
Ragaz J; Olivotto IA; Spinelli JJ; Phillips N; Jackson SM; Wilson KS; Knowling MA; Coppin CM; Weir L; Gelmon K; Le N; Durand R; Coldman AJ; Manji M
J Natl Cancer Inst; 2005 Jan; 97(2):116-26. PubMed ID: 15657341
[TBL] [Abstract][Full Text] [Related]
11. [Breast carcinoma--adjuvant chemo- and hormone therapy].
Fey MF
Ther Umsch; 1998 Jul; 55(7):413-4. PubMed ID: 9702106
[TBL] [Abstract][Full Text] [Related]
12. Tumor angiogenesis in women with node-positive breast cancer.
Folkman J
Cancer J Sci Am; 1995; 1(2):106-8. PubMed ID: 9166461
[No Abstract] [Full Text] [Related]
13. Oral uracil and tegafur compared with classic cyclophosphamide, methotrexate, fluorouracil as postoperative chemotherapy in patients with node-negative, high-risk breast cancer: National Surgical Adjuvant Study for Breast Cancer 01 Trial.
Watanabe T; Sano M; Takashima S; Kitaya T; Tokuda Y; Yoshimoto M; Kohno N; Nakagami K; Iwata H; Shimozuma K; Sonoo H; Tsuda H; Sakamoto G; Ohashi Y
J Clin Oncol; 2009 Mar; 27(9):1368-74. PubMed ID: 19204202
[TBL] [Abstract][Full Text] [Related]
14. Is the benefit of postmastectomy irradiation limited to patients with four or more positive nodes, as recommended in international consensus reports? A subgroup analysis of the DBCG 82 b&c randomized trials.
Overgaard M; Nielsen HM; Overgaard J
Radiother Oncol; 2007 Mar; 82(3):247-53. PubMed ID: 17306393
[TBL] [Abstract][Full Text] [Related]
15. Tamoxifen versus control after adjuvant, risk-adapted chemotherapy in postmenopausal, receptor-negative patients with breast cancer: a randomized trial (GABG-IV D-93)--the German Adjuvant Breast Cancer Group.
Kaufmann M; Graf E; Jonat W; Eiermann W; Geberth M; Albert US; Gademann G; Conrad B; Stahl K; von Minckwitz G; Schumacher M;
J Clin Oncol; 2005 Nov; 23(31):7842-8. PubMed ID: 16258087
[TBL] [Abstract][Full Text] [Related]
16. Adjuvant systemic therapy for breast cancer. Issues for primary care physicians.
Berkowitz LD; Love N
Postgrad Med; 1995 Oct; 98(4):85-8, 91, 94. PubMed ID: 7567725
[TBL] [Abstract][Full Text] [Related]
17. [Effectiveness of adjuvant systemic therapy in organ preserving treatment of pT1-2N0M0 breast cancer].
Semiglazov VF; Kanaev SV; Bugrova IL; Vlasov AN
Vopr Onkol; 1999; 45(5):516-9. PubMed ID: 10629708
[TBL] [Abstract][Full Text] [Related]
18. Adjuvant drug therapy for operable breast cancer.
Hudis CA; Norton L
Semin Oncol; 1996 Aug; 23(4):475-93. PubMed ID: 8757274
[TBL] [Abstract][Full Text] [Related]
19. Adjuvant systemic therapy for early breast cancer: progress and controversies.
Hortobagyi GN
Clin Cancer Res; 2001 Jul; 7(7):1839-42. PubMed ID: 11448893
[No Abstract] [Full Text] [Related]
20. [Adjuvant therapy in breast cancer].
Semiglazov VF
Vopr Onkol; 2000; 46(1):18-27. PubMed ID: 10789218
[No Abstract] [Full Text] [Related]
[Next] [New Search]
